KSHV REGULATION OF INNATE CYTOKINE RESPONSES AND T CELL ACTIVATION
KSHV 对先天细胞因子反应和 T 细胞激活的调节
基本信息
- 批准号:8167769
- 负责人:
- 金额:$ 21.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:Anti-Inflammatory AgentsAnti-inflammatoryAntigen-Presenting CellsAntigensBiological AssayBiological ModelsCancer EtiologyCell Culture TechniquesCell physiologyCell secretionCellsComputer Retrieval of Information on Scientific Projects DatabaseDataEnvironmentFundingGene TransferGenesGrantHerpesviridae InfectionsHumanHuman Herpesvirus 8ImmuneInfectionInstitutionInterleukin-10Interleukin-6InterventionKaposi SarcomaMusOutcome MeasurePalate Kaposi&aposs SarcomaPatientsPreventionProductionReactive Nitrogen SpeciesRegulationResearchResearch DesignResearch PersonnelResistanceResourcesSignal TransductionSourceSystemT cell responseT-Cell ActivationTestingUnited States National Institutes of Healthbasecytokinemalignant mouth neoplasmoutcome forecastresponsetreatment strategy
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Background
The Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS). Existing data suggest that T cell responses are critical for the control of KS progression, and antigen-presenting cells (APC) provide important activation signals for generating these responses. Whether KSHV infection of APC impairs effective T cell responses thereby promoting KS progression is unknown. Our model systems show that KSHV impairs T cell activation through multiple KSHV-encoded mechanisms involving infection of APC, including alteration of cytokine production by APC. Therefore, we propose to use these systems, including primary cells from human patients, to identify mechanisms for KSHV regulation of APC function and T cell activation.
Rationale
KSHV is the most common cause of cancer, and specifically oral cancers, arising in HIV-infected patients. Oral KS is resistant to existing therapies and portends an ominous prognosis. A better understanding of how KSHV regulates T cell activation through the infection of APC may provide new opportunites for developing immune-based or anti-inflammatory strategies for the treatment or prevention of oral KS.
Study design and outcome measures
Using human and murine APC as targets of KSHV infection and gene transfer in cell culture, we will first identify specific KSHV-encoded genes involved in APC secretion of immunoinhibitory molecules, including IL-6, IL-10, and reactive nitrogen species (RNS). Next, using antigen-independent and antigen-dependent T cell activation assays, we will test interventional strategies for reducing IL-6, IL-10, and RNS secretion by KSHV-infected APC and restoring T cell activation in this environment.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
背景
卡波西肉瘤相关疱疹病毒(KSHV)是卡波西肉瘤(KS)的病原体。现有的数据表明,T细胞应答对于KS进展的控制是至关重要的,并且抗原呈递细胞(APC)为产生这些应答提供重要的激活信号。KSHV感染APC是否损害有效的T细胞应答从而促进KS进展尚不清楚。我们的模型系统表明,KSHV通过多种KSHV编码的机制,涉及APC的感染,包括APC细胞因子的产生改变,损害T细胞活化。因此,我们建议使用这些系统,包括来自人类患者的原代细胞,以确定KSHV调节APC功能和T细胞活化的机制。
理由
KSHV是最常见的癌症原因,特别是在艾滋病毒感染患者中出现的口腔癌。口服KS对现有疗法有抵抗力,并预示着不祥的预后。更好地了解KSHV如何通过感染APC调节T细胞活化,可能为开发基于免疫或抗炎的策略来治疗或预防口腔KS提供新的机会。
研究设计和结局指标
使用人类和小鼠APC作为KSHV感染和细胞培养中基因转移的靶点,我们将首先鉴定出参与APC分泌免疫抑制分子(包括IL-6、IL-10和活性氮类(RNS))的特定KSHV编码基因。接下来,使用抗原非依赖性和抗原依赖性T细胞活化测定,我们将测试减少KSHV感染的APC分泌IL-6、IL-10和RNS并在此环境中恢复T细胞活化的干预策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher H Parsons其他文献
Phase I study of pembrolizumab in people with HIV and cancer.
帕博利珠单抗 (pembrolizumab) 在艾滋病毒和癌症患者中的 I 期研究。
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:45.3
- 作者:
T. Uldrick;P. Goncalves;Moh. Abdul Hay;A. Claeys;B. Emu;M. Ernstoff;L. Fong;J. C. Kaiser;H. Kohrt;Andreanne M. Lacroix;Steve Y Lee;Lisa M Lundgren;K. Lurain;Christopher H Parsons;Sharavi Peeramsetti;R. Ramaswami;E. Sharon;C. Wang;R. Yarchoan;M. Cheever - 通讯作者:
M. Cheever
Christopher H Parsons的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher H Parsons', 18)}}的其他基金
HIV Clinical Tumor Biorepository (HTCB) Core
HIV 临床肿瘤生物样本库 (HTCB) 核心
- 批准号:
10223344 - 财政年份:2017
- 资助金额:
$ 21.31万 - 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
- 批准号:
8790667 - 财政年份:2014
- 资助金额:
$ 21.31万 - 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
- 批准号:
8928574 - 财政年份:2014
- 资助金额:
$ 21.31万 - 项目类别:
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
一项评估 ABC294640 在难治性/再发性骨髓瘤患者中的早期临床试验
- 批准号:
9120662 - 财政年份:2014
- 资助金额:
$ 21.31万 - 项目类别:
KSHV REGULATION OF INNATE CYTOKINE RESPONSES AND T CELL ACTIVATION
KSHV 对先天细胞因子反应和 T 细胞激活的调节
- 批准号:
8360484 - 财政年份:2011
- 资助金额:
$ 21.31万 - 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
- 批准号:
8403765 - 财政年份:2010
- 资助金额:
$ 21.31万 - 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
- 批准号:
8206648 - 财政年份:2010
- 资助金额:
$ 21.31万 - 项目类别:
Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis
脂质代谢和 KSHV 相关淋巴瘤发病机制
- 批准号:
7928552 - 财政年份:2010
- 资助金额:
$ 21.31万 - 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
- 批准号:
8588216 - 财政年份:2010
- 资助金额:
$ 21.31万 - 项目类别:
Regulation of the Tumor Microenvironment by KSHV
KSHV 对肿瘤微环境的调节
- 批准号:
7929373 - 财政年份:2010
- 资助金额:
$ 21.31万 - 项目类别:
相似海外基金
Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
- 批准号:
23K07659 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
- 批准号:
23K15705 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
- 批准号:
23K19490 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
- 批准号:
10697567 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
- 批准号:
10727765 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
- 批准号:
23K08467 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
- 批准号:
23K13905 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
- 批准号:
2223225 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:
Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
- 批准号:
10651054 - 财政年份:2023
- 资助金额:
$ 21.31万 - 项目类别:














{{item.name}}会员




